心力衰竭药物治疗新进展：2007

www.yongyao.net　　2009-9-30 14:16:46　　来源：　　责任编辑：

分享到：

9 参考文献
［1］Rosamond W，Flegal K，Friday G，et al.Heart disease and stroke stat- istics- 2007 update：a report from the American Heart AssociationStatistics Committee and Stroke Statistics Subcommittee.
Circulation，2007，115：e69- e171.
［2］Padia SH，Kemp BA，Howell NL，et al. Conversion of renal angiotensinⅡ to angiotensin Ⅲ is critical for AT2 receptor- mediated natriuresis in rats. Hypertension，2008，51：460- 465.
［3］Ramírez- Expósito MJ，Martínez- Martos JM. Hypertension，RAS，and gender：what is the role of aminopeptidases？Heart Fail Rev，2008，24［Epub ahead of print］.
［4］Banegas I，Prieto I，Vives F，et al.Brain aminopeptidases and Hypertens-ion.J Renin Aldoster syst，2006，7：129- 134.
［5］Schrier RW，Gross P，Gheorghiade M，et al. Tolvaptan，a selective vaso- pressin V2- receptor antagonist，for hyponatremia.N EnglJ Med，2006，355：2099- 2112.
［6］Yancy CW.Climbing the mountain of acute decompensated heart failure- the EVEREST Trials.JAMA，2007，297：1374- 1376.
［7］ Gheorghiade M，Konstam MA，Burnett JC Jr，et al.Short - term clinical effects of tolvaptan，an oral vasopressin antagonist，in patients hospitalized for heart failure： the EVEREST Clinical
Status Trials. JAMA，2007，297：1332- 1343.
［8］Ramasubbu K，Mann DL，Deswal A.Anti- angiotensin therapy：new perspectives. Cardiol Clin，2007，25：573- 580.
［9］Gradman AH，Kad R.Renin inhibition in hypertension.J Am CollCardiol，2008，51：519- 528.
［10］Cleland JG，Abdellah AT，Khaleva O，et al.Clinical trials update from the European Society of Cardiology Congress 2007：3CPO，ALOFT，PROSPECT and statins for heart failure.Eur J Heart Fail，2007，9：1070- 1073.
［11］ Recio - Mayoral A，Kaski JC，McMurray JJ，et al.Clinical trials update from the European Society of Cardiology Congress in Vienna， 2007： PROSPECT， EVEREST， ARISE， ALOFT，FINESSE，Prague- 8，CARESS in MI and ACUITY. Cardiovasc Drugs Ther，2007，21：459- 465.
［12］Cleland JG，Coletta AP，Clark AL.Clinical trials update from the American College of Cardiology 2007：ALPHA， EVEREST，FUSION II，VALIDD，PARR- 2，REMODEL，SPICE，COURAGE，COACH，REMADHE，pro- BNP for the evaluation of dyspnoea and THIS- diet.Eur J Heart Fail，2007，9：740- 745.
［13］ Miracle CM，Rieg T，Blantz RC，et al.Combined effects of carbonic an - hydrase inhibitor and adenosine A1 receptor antagonist on hemodynamic and tubular function in the kidney.Kidney Blood Press Res，2007，30：388- 399.
［14］ Landmesser U，Drexler H.Update on inotropic therapy in the management of acute heart failure.Curr Treat Options CardiovascMed. 2007，9：443- 449.
［15］ Archan S，Toller W.Levosimendan：current status and future prospects. Curr Opin Anaesthesiol，2008，21：78- 84.
［16］Kamat SA，Gandhi SK，Davidson M.Comparative effectiveness of rosuvastatin versus other statin therapies in patients at increased risk of failure to achieve low- density lipoprotein goals.Curr Med
Res Opin，2007，23：1121- 1130.
［17］Athyros VG，Kakafika AI，Tziomalos K，et al.CORONA，Statins，and Heart Failure：Who Lost the Crown Angiology，2008，59：5- 8.
［18］Dominiak M.Rosuvastatin in patients with heart failure - novelpoint of view on pleiotropic actions of statins on the basis of data from CORONA study.Kardiol Pol，2008，66：114- 116.